Exporter

EN
FR
Methotrexate
Statut de médicament essentiel
Description générale

INN
Methotrexate
Codes ATC
L01BA01 L04AX03
Type de médicament
Chemical agent
Historique des statuts LME
Demande refusée en 2023 (TRS 1049) pour Crohn disease site
Demande refusée en 2023 (TRS 1049) pour Psoriatic arthritis
Wikipédia
Methotrexate
DrugBank
Methotrexate
Recommandations
Section
Cytotoxic medicines
  • Parenteral > General injections > IV: 50 mg in vial (as sodium salt); 50 mg per 2 mL; 1000 mg per 10 mL concentrated injection
  • Oral > Solid: 2.5 mg (as sodium salt)
  • Parenteral > General injections > IV: 50 mg in vial (as sodium salt)
Indications
Malignant neoplasms of breast Malignant trophoblastic neoplasms of placenta Osteosarcoma of bone and articular cartilage of unspecified sites Lymphoid leukaemia, not elsewhere classified Acute myeloid leukaemia with recurrent genetic abnormalities Unspecified malignant neoplasms of ill-defined or unspecified sites Burkitt lymphoma including Burkitt leukaemia Anaplastic large cell lymphoma, ALK-positive Anaplastic large cell lymphoma, ALK-negative Langerhans cell histiocytosis
Section
Disease-modifying anti-rheumatic drugs (DMARDs)
  • Oral > Solid > tablet: 2.5 mg (as sodium salt)
Indications
Rheumatoid arthritis, serology unspecified
Section
Medicines for juvenile joint diseases
  • Oral > Solid > tablet: 2.5 mg (as sodium salt)
Indications
Juvenile idiopathic arthritis
Section
Dermatological medicines > Medicines affecting skin differentiation and proliferation
  • Oral > Solid > tablet: 2.5 mg (as sodium salt); 10 mg (as sodium salt)
Indications
Psoriasis of unspecified type
Section
Immunomodulators for non-malignant disease
  • Parenteral > General injections > SC: pre-filled syringe in multiple strengths
Indications
Crohn disease site Psoriatic arthritis